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INTRODUCTION
Regional myocardial blood ﬂow can now be mea-
sured noninvasively in units of milliliters blood per
minute per gram myocardium. These noninvasive mea-
surements are not conﬁned to a speciﬁc imaging
modality but are available with MRI, CT, and PET,
although, thus far, most investigations of the coronary
circulation in humans have employed PET ﬂow mea-
surements. Flow estimates with these different imaging
modalities were found in animal experiments to correlate
well with invasive ﬂow estimates by the arterial blood
sampling-microsphere technique widely considered as
the ‘‘gold standard’’ of ﬂow measurements.
1-11 In these
comparison studies, noninvasively-derived estimates
corresponded linearly with invasively-measured myo-
cardial blood ﬂows over a wide ﬂow range, i.e., from as
low as 0.3 mL/minute/g to as high as 5-6 mL/minute/g.
When tested in the human heart, noninvasive ﬂow esti-
mates correlated well with those obtained through
invasively-obtained indices of ﬂow and its changes by
well-established alternate measurement approaches.
12-16
Development and commercial availability of user-
friendly software programs have facilitated the use of
these new measurement capabilities so that they are now
readily available in the clinical environment for the study
of patients with cardiovascular disease.
As several investigations have indicated, measure-
ments of myocardial blood ﬂow at rest contain only
limited diagnostic information. For example, even in
patients with advanced cardiovascular disease such
as nonischemic dilated or ischemic cardiomyopathy,
hypertrophiccardiomyopathy,orcoronaryartery disease,
resting myocardial blood ﬂows frequently are similar to
those in normal individuals.
17-19 It is the response of
myocardial blood ﬂow to speciﬁcally-targeted pharma-
cological or physiological interventions that can uncover
the presence of functional or structural disease-related
alterations of the coronary circulation. This then under-
scores the need for closely examining these targets and
how they relate to anatomical and functional determi-
nants of coronary blood ﬂow and, by inference, to
myocardial blood ﬂow and their alterations in cardio-
vascular disease. Local and systemic mechanisms
regulate the complex interactions between ﬂow and
anatomy in order to meet the heart’s energy needs.
A comprehensive description of the coronary circulatory
function and its control exceeds the scope of this review
so thatthe interested reader isreferred to detailed reviews
on this topic.
20,21 This review then seeks to describe in
broad strokes the major functional and anatomical
determinants of coronary blood ﬂow as they pertain to
noninvasive measured myocardial blood ﬂows.
DETERMINANTS OF MYOCARDIAL
BLOOD FLOW
Conceptually, the coronary circulation can be divi-
ded into two compartments, the large epicardial conduit
vessels and the resistance vessels, typically less than
300 lm in diameter (Figure 1). Whereas the conduit
vessels exert little if any resistance to ﬂow, resistance to
ﬂow progressively rises as the vessel diameter of the
resistance vessels declines from about 300 lmi nt h e
small arteries to less than 100 lm in the arteriolar ves-
sels.
20,21 Exchange of substrates between blood and
tissue occurs at the level of the capillaries.
Flow across the myocardium largely depends on the
pressure gradient between the aortic root (the ‘‘coronary
driving pressure’’) and the right atrium. Under normal
conditions, the driving pressure is fully maintained
along the epicardial conduit vessels with little if any
pressure loss in the distal epicardial arteries. However,
intra-coronary pressures decline along the microvascu-
lature (with most of the pressure dissipating in the
300-100 lm diameter vessels) until reaching a pressure
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545of 20-30 mmHg, still adequate to ascertain a gradient
across the capillaries. Additional determinants of the
resistance to ﬂow include extravascular resistive forces
that are directly related to the left ventricular systolic
pressure, the contractile state of the myocardium and the
heart rate.
Auto-regulatory mechanisms coordinate the inter-
action between intra-coronary driving pressure and
microvascular resistance in order to maintain adequate
ﬂow across the capillaries for substrate delivery and
removal. Through this mechanism (also deﬁned as
‘‘coronary autoregulation’’), decreases in driving pres-
sure are compensated for by decreases in resistance and
conversely, increases in driving pressure by increases in
resistance so that ﬂow remains constant for a given
cardiac workload. This regulatory mechanism operates
within the range of physiologic arterial pressures but
fails during hypotension when ﬂows become strongly
dependent on the driving pressure.
22
Changes in myocardial work and, thus, in energy
demand, are accompanied by proportionate changes in
coronary and, thus, myocardial blood ﬂow. For example,
as shown with noninvasive PET measurements, a
2.8-fold increase in cardiac work (estimated from the
rate pressure product) with supine bicycle exercise was
matched by a 2.2-fold increase in ﬂow.
23 Similarly,
dobutamine infusion in patients with coronary artery
disease raised the rate pressure product by a factor of 2.2
that was paralleled by a 2.4-fold increase in ﬂow in
myocardial territories subtended by normal coronary
arteries (Figure 2).
24
Work-related ﬂow increases are initiated by a met-
abolically-mediated decrease in microvascular resis-
tance, possibly involving adenosine as a metabolite of
adenosine monophosphate and causing vascular smooth
muscle relaxation. The resulting ﬂow increase is aug-
mented by endothelium-dependent factors; higher ﬂow
velocities exert greater shear-stress upon the endothe-
lium with stimulation of the endothelial nitric oxide
synthase (eNOS) and release of the smooth muscle-
relaxing nitric oxide (NO). In this scenario, endothelial
cells closely interact with vascular smooth muscle cells
in order to adjust the vessel diameter to changes in ﬂow
velocities (‘‘ﬂow-mediated dilation’’), both at the level
of the microvessels and the epicardial conduit vessels
(Figure 3).
25
Major determinants of the resistance to ﬂow include
the intra-vascular pressure, the velocity of ﬂow, the
length of the vessel and, importantly, its diameter.
Applying the Hagen-Poisseuil equation, resistance to
ﬂow depends on the fourth power of the vessel diameter.
High velocity ﬂows in the epicardial conduit vessels
lead to greater shear-stress on the endothelial cells,
prompting an endothelium-dependent, ﬂow-mediated
dilation of the conduit vessels and thus a resetting of
Figure 2. Relationship of myocardial blood ﬂow to cardiac
work as reﬂected by the rate pressure product. Myocardial
blood ﬂow was measured with N-13 ammonia at baseline and
again during intravenous dobutamine infusion. Regional
myocardial blood ﬂows in myocardial territories supplied by
nondiseased vessels are shown in green. In contrast, regional
myocardial blood ﬂows in territories subtended by diseased
coronary vessels are shown in red. Adopted from Krivokapich
et al.
34
Figure 3. This highly simpliﬁed cartoon depicts the interac-
tion between endothelial and vascular smooth muscle cells
during pharmacologic vasodilation during physical stress.
Figure 1. Highly schematic depiction of the main anatomic
features of the coronary circulation (see text).
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accommodate high velocity ﬂows. This ﬂow-mediated
conduit vessel dilation, when measured on quantitative
coronary angiography, serves as an index of endothelial
function. Characteristically, the cross-sectional area of
the vessel increases by about 20% to 30% in response
to pharmacologically stimulated hyperemia.
26,27 As a
result of the ﬂow-mediated vasodilation, intra-coronary
pressures are fully maintained along the large epicardial
coronary arteries as demonstrated with intra-coronary
pressure transducers.
28
Both, endothelial and vascular smooth muscle cells
express adreno-receptors and thus respond to regional
and systemic sympathetic stimuli. For example, local
release of norepinephrine from adrenergic nerve termi-
nals in the coronary arteries and release of cate-
cholamines from the adrenal glands into the circulation
during sympathetic stress or physical exercise lead to an
a-adreno-receptor-mediated vascular smooth muscle
constriction which under normal conditions is opposed
by an adrenergically-mediated release of vasodilator
substances (primarily NO) from the endothelial cell. This
ﬁnely tuned interaction between vasoconstrictive (mostly
vascular smooth muscle dependent) and vasodilator
forces (mostly endothelium related) recalibrates the
vessel diameter against the ﬂow velocity in order to
maximally reduce resistance to ﬂow (Figure 3).
Vasodilator effects of the endothelial cell are
attributed here to NO as the dominant vasoactive endo-
thelium-related substance. Actually, the endothelium
releases several vasoactive substances with relaxing or
constricting vascular smooth muscle effects.
20 It is also
important to emphasize the pivotal role of the endothe-
lium in protecting against atherosclerosis, thrombosis,
and ﬁbrin deposition. Exposure to nonlaminar ﬂow,
modiﬁed lipoproteins, or inﬂammatory cytokines leads to
mechanical, immunological, and chemical injury of the
endothelium. Modiﬁed lipoproteins or insulin resistance
for example may interfere with cellular signal transduc-
tion systems or impair receptor function, thus reducing
the rate of eNOS activity and the bioavailability of NO
that may be further diminished by increased rates of
inactivation due to oxygen reactive species. Dysfunction
and injury are associated with ‘‘endothelial activation’’
and loss of its atheroprotective and antithrombotic
properties, when expression of adhesion molecules and
production of cytokines and chemo-attractants promote
the atherosclerotic process.
Targets of Noninvasive Flow Measurements
Image-based determinations of myocardial blood
ﬂows require, besides measurements of the myocardial
tissue tracer concentrations and kinetics, determination
of the arterial tracer input function. The latter is typi-
cally derived from serial images acquired during the
initial tracer transit through the central circulation.
Acquisition of this image sequence during and after the
tracer administration is fundamental to most ﬂow mea-
surements but limits investigations of the myocardial
blood ﬂow during upright treadmill or bicycle exercise.
Some studies have employed physical stress with supine
bicycle exercise with the subject positioned in the
imaging device.
23,29,30 In general however, image-based
assessments of coronary circulatory function are per-
formed with the subject positioned in the imaging
device. These assessments employ (a) pharmacological
stress with vascular smooth muscle relaxing agents (as
for example dipyridamole, adenosine, adenosine–
triphosphate, and more recently, adenosine receptor
subtype A2A agonists like regadenosone)
31-33; (b) phar-
macologic inotropic stimulation (with for example
intravenous dobutamine)
34,35; and (c) sympathetic
stimulation with cold pressor testing.
36 Each type of
intervention targets different components or determi-
nants of the coronary circulation.
Vasodilator stress. Pharmacological vasodila-
tor stress seeks to maximally lower the vascular
resistance through relaxation of the vascular smooth
muscle cell at the level of the microcirculation, thereby
uncoupling coronary ﬂow (supply) from myocardial
work (demand). Flows during vasodilator-induced
hyperemia then depend largely on the coronary driving
pressure and, thus, on the arterial blood pressure, and the
residual coronary resistance. Despite considerable inter-
individual variations, pharmacologic stress induces on
average three to ﬁvefold increases in blood ﬂow in
normal individuals with hyperemic blood ﬂows ranging
from 2 to 4 mL/minute/g (depending on the type of
measurement approach, the ﬂow tracer used, and the
type of image analysis).
Maximum hyperemic ﬂows reﬂect the total vaso-
dilator capacity of the coronary circulation. Because
blood ﬂow during pharmacologically-stimulated vaso-
dilation strongly depends on the driving pressure, the
‘‘minimal coronary vascular resistance (CVR)’’ (as the
ratio of mean arterial blood pressure over myocardial
blood ﬂow) serves as another index of the coronary
vasodilator capacity that is however normalized to the
perfusion pressure. Moreover, the coronary (or more
appropriately, myocardial) ﬂow reserve has also been
accepted as another measure of the vasodilator capacity.
It reﬂects the ratio of hyperemic over rest myocardial
blood ﬂow which limits its accuracy because the
term ‘‘ﬂow reserve’’ not only reﬂects the maximally-
achieved hyperemic blood ﬂow, but depends also on
myocardial blood ﬂow at rest. In patients with hyper-
tension for example, ﬂows at rest are elevated due to the
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blood ﬂows are in the range of normal, the actual ﬂow
reserve may be diminished. Some laboratories therefore
adjust resting blood ﬂows to cardiac work by normal-
izing ﬂows to the rate pressure product. The ﬂow reserve
is then reported as the ratio of hyperemic to ‘‘normal-
ized’’ resting blood ﬂows.
Vasodilator-stimulated ﬂows also depend on extra-
vascular resistive forces. Addition of handgrip stress or
supine bicycle exercise in order to raise the coronary
perfusion pressure during pharmacologic vasodilation
produced decreases rather than increases of hyperemic
ﬂows by about 10% to 15%
29,37 because of an increase
in extravascular resistance due to higher heart rates,
systolic blood pressures, and contractility.
Although pharmacological vasodilator stress targets
the vascular smooth muscle, the ﬂow response reﬂects
the ‘‘total integrated vasodilator capacity’’ of the
coronary circulation. It includes the contribution of
endothelium-related regulatory mechanisms. Pharma-
cologic inhibition of eNOS with intravenous L-NAME
in young, normal volunteers signiﬁcantly attenuated the
hyperemic response.
38 Hyperemic ﬂows after eNOS inhi-
bition averaged only 1.50 ± 0.55 mL/minute/g as com-
pared to 1.90 ± 0.33 mL/minute/g at baseline, reﬂecting
a 21% loss in total vasodilator capacity or an about 18%
decrease in myocardial ﬂow reserve attributed to
impaired endothelium-related vasodilator forces in both,
the microvessels and the conduit vessels.
Positive inotropic stimulation. Pharmaco-
logic inotropic stimulation serves as an alternate to
physical stress. Intravenous administration of dobuta-
mine, a synthetic sympathomimetic amine with a
dominant positive inotropic effect via stimulation of
b- and a-adrenoreceptors produces signiﬁcant increases
in myocardial oxygen consumption (MVO2) which are
associated with commensurate increases in myocardial
blood ﬂow. Infused at a rate of 40 lg/kg/minute in 11
normal subjects, dobutamine raised MVO2 by an aver-
age of 280 ± 80% while myocardial blood ﬂow
increased by an average of 200 ± 80%.
35 The dobuta-
mine-induced changes in MVO2 correlated closely with
changes in myocardial work and, further, myocardial
blood ﬂow (Figure 2).
Sympathetic stress. Sympathetic stimulation
with for example cold pressor testing more speciﬁcally
targets endothelium-related determinants of the coronary
circulatory function. The sympathetic response to cold
exposure includes prompt increases in heart rate and
systolic blood pressure together with local norepineph-
rine release from adrenergic nerve terminals in the
coronary circulation.
36,39 The increase in myocardial
work as reﬂected by the increase in the rate pressure
product is under normal conditions associated with a
proportionate increase in myocardial blood ﬂow.
36
Again, a metabolically initiated, work-related increase
in ﬂow is augmented by endothelium-related vasodilator
forces. Adrenergically-mediated vasoconstrictor effects
on the vascular smooth muscle are balanced by largely
endothelium-related vasodilator forces affecting both the
microvasculature and the epicardial conduit vessels.
25 In
one study in 50 normal volunteers, cold pressor testing
produced an average 38% increase in rate pressure
product that was associated with a 30% average rise in
myocardial blood ﬂow.
36
Flow responses to cold pressor testing are reported
as absolute ﬂows during cold exposure and are compared
to ﬂows at baseline, or, as a percent ﬂow increase from
baseline to cold stimulation. Analogous to the ﬂow
reserve, such percent increase does depend on baseline
blood ﬂow. Further, use of delta MBF (mL/minute/g) as a
measure of the ﬂow response is preferable because of its
lesser dependency on baseline myocardial blood ﬂow.
36
The degree of endothelium-dependent modulation
of ﬂow during sympathetic stimulation appears to cor-
respond to the endothelium-related ﬂow augmentation
during pharmacologically stimulated hyperemia. For
example, in healthy subjects without coronary risk fac-
tors, the change in vascular resistance in response to
cold pressor testing was signiﬁcantly correlated with the
adenosine- or dipyridamole-induced decline in CVR,
suggesting proportionate contributions of endothelium-
related mechanisms to both types of ﬂow responses
(Figure 4).
36
Figure 4. Changes in the CVR in response to cold pressor
testing are compared to changes in the CVR during adenosine
or dipyridamole stimulated hyperemia. Adopted from Prior
et al.
36
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FUNCTION
Quantitative measurements of myocardial blood
ﬂow hold considerable clinical promise in several areas.
They include identiﬁcation of functional rather than
structural disturbances that may reﬂect adverse effects of
coronary risk factors on endothelial function or early
stages of developing coronary artery disease that can
signify an increased cardiac risk. Moreover, demon-
stration of endothelial dysfunction may identify alter-
ations as potentially reversible in response to risk
lowering therapeutic strategies so that in turn, ﬂow
measurements may also prove useful for monitoring
treatment responses. Another important aspect of ﬂow
measurements is the ability to characterize extent and
severity of coronary artery disease. Finally, such mea-
surements offer a means for assessing the total ischemic
burden of the myocardium due to macrovascular and
microvascular disease. Assessment of the ischemic
burden, as several studies have demonstrated, contains
considerable prognostic information.
17-19
Functional Alterations Without Apparent
Structural Correlates
Investigations in asymptomatic patients with
hyperlipidemia but without clinical evidence of coro-
nary artery disease or in patients with diabetes, all with
normal stress–rest perfusion images, have reported sta-
tistically signiﬁcant reductions of the total integrated
vasodilator capacity.
40-43 This impairment, as reported
by other investigations, appears wholly or partially revers-
ible as aggressive lipid lowering treatment or glucose
controlindiabeticpatients was associatedwithsigniﬁcant,
30% to 50% improvements in the total vasodilator
capacity.
44-48
Conventional coronary risk factors such as hyper-
cholesteremia or hyperglycemia are known to adversely
affect endothelial function. Improvements in coronary
vasomotor function as reﬂected by decreases in the total
vasodilator capacity and as observed after lipid- or
glucose-lowering were likely due to improvements or
restoration of endothelial function in the coronary con-
duit and resistance vessels; a possibility supported by
ﬁndings of improved or even normal endothelium-
mediated ﬂow responses to cold pressor testing in type 2
diabetes patients in response to glucose-lowering,
possibly mediated by decreases in oxygen reactive
species.
49
Depending on the severity of coronary risk or
the number of risk factors, functional alterations may
initially remain conﬁned to endothelium-related com-
ponents without yet affecting the total integrated
vasodilator capacity. For example, while the total
vasodilator capacity was found to be statistically sig-
niﬁcant diminished only in patients with clinically
documented type 2 diabetes as the most severe form of
insulin resistance, less severe states of insulin resistance
like euglycemic insulin resistance and impaired glucose
tolerance were associated with normal vasodilator
capacities.
50 Importantly however, ﬂow responses to
sympathetic stimulation were signiﬁcantly diminished
even in the presence of insulin resistance alone with
normal circulating glucose levels. Flow responses to
cold pressor testing progressively worsened with more
severe states of insulin resistance, possibly as a function
of the number of risk factors. In this scenario, the normal
balance between vasodilator and vasoconstrictive forces
was no longer maintained. Reductions in NO bioavail-
ability may have limited vasodilator responses so that
vasoconstrictor forces, largely mediated through
a-adrenergic stimulation during cold pressor testing
dominated and attenuated the normal ﬂow response.
Disturbances in conduit vessel func-
tion. Values of hyperemic ﬂows in individuals with
risk factors for coronary artery disease are usually
reported as global values, i.e., averaged over the entire
left ventricular myocardium. This is important as a
diminished or absent ﬂow-related dilation of the large
epicardial vessels during hyperemia can cause a pro-
gressive decline in intra-coronary pressure and thus, in
myocardial perfusion along the coronary epicardial
artery.
28,51 Accordingly, myocardial perfusion, espe-
cially during hyperemia, progressively declines in the
base-to-apex direction. Indeed, such longitudinal ﬂow
decreases have been reported in the absence of discreet
coronary stenoses and in patients with conventional risk
factors for coronary artery disease but without apparent
clinical coronary vascular disease.
51-53 In these investi-
gations, hyperemic ﬂows in the apical portions of the left
ventricular myocardium were on average 10-20% lower
than those in the basal portions (Figure 5). Hyperemic
ﬂows in the basal portion of the left ventricular myo-
cardium may be normal but are diminished in the apical
portions so that estimates of hyperemic ﬂows when
averaged of the entire myocardium may still be within
the range of normal.
Different from pharmacologically-induced hyper-
emia where the ﬂow-mediated vasodilation is dimin-
ished or absent, sympathetic stress may cause an
actual decline in luminal diameter or ‘‘paradoxical
vasoconstriction’’ as observed on quantitative angiog-
raphy.
27,53,54 Accordingly, for a constant ﬂow but a
smaller vessel lumen, resistance to ﬂow increases and
intra-coronary pressures progressively decline along the
epicardial conduit vessels. The longitudinal perfusion
gradient thus offers a means for assessing the epicardial
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tional alone, other factors such as increases in vessel
stiffness, outward vascular remodeling, or diffuse
luminal narrowing may account for an attenuated ﬂow-
mediated dilation and, thus, for the longitudinal perfu-
sion gradient.
51,52
Assessment of Extent and Severity
of Coronary Artery Disease
When ﬂuid-dynamically signiﬁcant coronary artery
disease is present, the site of resistance to ﬂow moves
partially or fully from the microvessels to the epicardial
conduit vessels. At rest, ﬂow across ﬂuid-dynamically
signiﬁcant stenoses is frequently maintained as long as
an adequate trans-stenotic pressure gradient can be
maintained by a downstream, compensatory decrease in
resistance. As most or all of the microvascular resistance
reserve is already spent for maintaining this trans-
stenotic pressure gradient at rest, the vessel’s ability to
respond to vasodilator stimulation becomes impaired or
is lost. Hence, vasodilator stress no longer elicits an
adequate ﬂow increase. The degree of impairment then
depends on the stenoses severity as reported for vaso-
dilator stress and for inotropically-stimulated myocar-
dial work increases (Figures 2 and 6).
34,55,56
While no deﬁnitive threshold values of hyperemic
ﬂows have thus far been established, myocardial ﬂow
reserves of less than 2.0 or 2.5, based on ﬁndings with
intra-coronary ﬂow velocity probes, are now widely
accepted as the lower limit of normal. Applying such
threshold values in patients with triple vessel disease,
quantiﬁcation of the myocardial ﬂow response to
hyperemic stress proved superior to standard myocardial
perfusion imaging for detecting accurately the number
of diseased vessels and thus the extent of coronary artery
disease.
57 Similar ﬁndings were reported in a more
recent study where however absolute hyperemic
ﬂows rather than values of ﬂow reserve downstream
of angiographically-stenosed coronary vessels more
Figure 5. Longitudinal myocardial perfusion gradient during pharmacologically-
stimulated vasodilation in normal volunteers without risk factors for coronary artery
disease (blue) and in normal volunteers but with conventional risk factors. The panel
on the left depicts a cartoon of the left ventricular myocardium and indicates the sites
of blood ﬂow measurements, with ‘‘base’’ for measurements in the left mid-ventricle
and ‘‘apex’’ for measurements in the more apical portion of the let ventricular
myocardium. Hyperemic ﬂows recorded in these areas are depicted on the right; they
are nearly identical in the two regions in the normal volunteers without risk factors but
differ in individuals with risk factors with signiﬁcantly lower ﬂows in the apical than
in the mid-ventricular region. Courtesy of Schindler et al from UCLA.
Figure 6. Inverse correlation between regional myocardial
blood ﬂow during dobutamine stress and the percent coronary
diameter stenosis as determined by quantitative coronary
angiography. Adopted from Krivokapich et al.
34
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perfusion imaging identiﬁed the presence of obstructive
coronary artery disease.
58
Flow responses to vasodilator stress in coronary
artery disease may differ from those during physical
exercise. Instead of an attenuated or absent ﬂow-medi-
ated conduit vessel dilation, physical stress may, as
mentioned above, actually lead to a decrease in the
vessel lumen or the stenosis diameter, possibly due to
increased a-adrenergically-stimulated smooth muscle
constriction or release of vasoactive substances from the
endothelium. Such vasoconstrictive effects during
exercise may indeed account for the more severe per-
fusion defects noted in one study after physical exercise
when compared to standard vasodilator stress.
59
Structural vs Functional Parameters
of Coronary Stenoses
Measurements of regional ﬂow responses to
vasodilator stress or inotropic stimulation can uncover
and quantify the ﬂuid-dynamic signiﬁcance of stenoses.
Hence, these functional measures of coronary artery
disease differ from structural indices as for example
percent luminal narrowing as deﬁned MSCT coronary
angiography. MSCT coronary angiography accurately
identiﬁes presence or absence of structural coronary
artery disease.
60-62 However, less than half of all cor-
onary lesions deﬁned as obstructive by MSCT are
associated with stress-induced defects.
63 Conversely,
stress-induced ﬂow defects are also seen in territories
supplied by only mildly diseased coronary vessels on
MSCT angiography. These disparate ﬁndings under-
score fundamental differences between structural and
functional alterations of coronary disease. The limited
spatial resolution of MSCT may contribute to this
disparity.
64 Yet, they are also related to insufﬁcient
descriptors of structural properties of coronary steno-
ses. Rather than depending on only the degree of
luminal narrowing, the functional signiﬁcance is multi-
factorial and depends for example on the length of the
stenosis, its eccentricity, its in- and outﬂow angles and
surface properties. Also, functional adaptations to
structural disturbances are possible. This then raises
questions as to the value of functional vs structural
stenosis properties for deﬁning the cardiac risk and for
predicting the long-term outcome of patients. Available
follow-up data on patients, gathered over 14-16 months
on average, support the accuracy of MSCT in effec-
tively ruling out the coronary artery disease, as
indicated by high event-free survivals.
65,66 However,
long-term follow-up studies will be needed to assess
the prognostic value of structural vs functional conse-
quences of coronary artery disease.
Microvessel Disease in the Absence
of Apparent Macrovascular Alterations
Clinically most useful are measurements of myo-
cardial blood ﬂow in patients with angiographically
nonidentiﬁable coronary disease or with disease con-
ﬁned to the microvasculature. This includes diffuse
luminal narrowing without discreet coronary stenosis,
51
systemic vasculopathies associated with inﬂammatory
disorders,
67 transplant vasculopathies,
68 or microangi-
opathies as for example in diabetes,
69 or in hypertrophic
cardiomyopathy.
17 Flow disturbances in these disorders
are either functional or structural in origin or both. Even
in the presence of symptoms of myocardial ischemia,
due to the diffusiveness of these orders, myocardial
perfusion images both at stress and rest are character-
istically normal. While myocardial blood ﬂow, when
measured under resting conditions, will most likely be in
the range of normal in these disorders, its response to
vasodilator stress is typically diminished. In patients
with type 2 diabetes for example, hyperemic ﬂows were
on average 27% lower than in a comparison group of
normal volunteers (Figure 7).
42,48 The degree of vaso-
dilator impairment in these patients was related to
plasma glucose levels and further, to glycemic control.
Hyperemic ﬂows in glycemically-controlled patients
signiﬁcantly exceeded those in poorly controlled
patients. If however associated with structural micro-
vascular disease, hyperemic responses to dipyridamole
and thus to the total vasodilator capacity were found to
be even more severely impaired.
69
Severe restrictions in the vasodilator reserve as
observed in patients with nonischemic dilated cardio-
myopathy,
18 with hypertrophic cardiomyopathy,
17 or
advanced ischemic cardiomyopathy with diminished left
Figure 7. Myocardial ﬂow reserve in patients with type 2
diabetes or in patients with type 2 diabetes and microvascular
disease as compared to normal control individuals. Data taken
from Yokoyama et al.
42,48,69
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19 reﬂect the total ischemic burden.
In these investigations, ﬂow reserves of less than 1.5
were highly predictive of poor long-term outcomes in
terms cardiac mortality and progression to heart failure.
Even in the absence of signiﬁcant macrovascular disease
or coronary stenoses, the ischemic burden resulting from
severe microvascular impairments equals that of a
severe coronary stenosis. Using the now classic rela-
tionship between the severity of coronary stenosis and
the coronary ﬂow reserve, a myocardial ﬂow reserve of
less than 1.5 will be equivalent to an about 90% to 95%
coronary stenosis.
70
Increases in microvascular resistance and, thus,
reductions in the total integrated vasodilator capacity
can be caused by functional disturbances, by structural
alterations, or by both. Functional disturbances may
involve not only the endothelium but also the vascular
smooth muscle, possibly as a function of the number of
risk factors.
50 Flow responses to interventions primarily
targeting the endothelium may thus already be abnormal
even though the total vasodilator capacity may still be
preserved. Primarily functional disturbances may
potentially be reversible as demonstrated for example
after glucose-lowering in type 2 diabetes, lipid-lowering
in patients with hypercholesterolemia, or administration
of antioxidants.
44-48,71,72 In contrast, structural altera-
tions as the cause of microvascular impairments may
involve remodeling of the intramural arterioles with
thickening of the intima and media layers, as reported
for hypertrophic cardiomyopathy,
73 increases in peri-
vascular ﬁbrosis and reductions in vessel density,
i.e., decreases in the number of arterioles per unit
mass myocardium as for example in nonischemic
cardiomyopathy.
74
SUMMARY AND CONCLUSIONS
It is clear now that measurements of myocardial
blood ﬂow in absolute units expand the current scope of
noninvasive studies of the human circulatory function.
While this new capability allows improved character-
ization of the extent and severity of coronary artery
disease, its impact is likely to be the greatest in patients
with microvascular disorders. It is in this particular
disease entity where ﬂow measurements offer a means
for estimating the true ischemic burden of the myocar-
dium and its associated cardiac risk. Further, it is in
these patients, where targeting different aspects of cor-
onary vasomotion with ﬂow measurements can aid in
determining the severity of disease, distinguish between
functional and structural alterations and, at the same
time, identify potential reversibility and thus therapeutic
strategies.
71,72
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